ATRA | Atara Biotherapeutics Inc. Stock Price & News - WSJ View the latest Atara Biotherapeutics Inc. (ATRA) stock price, news, historical charts, analyst ratings and financial information from WSJ. 3 Biotech Stocks With Jaw-Dropping Growth Potential Jan 28, 2018 · Biotech stocks have consistently produced market-beating gains for investors for the bulk of the past seven years. In fact, biotech companies made up a whopping eight of the 10 top-performing
Dec 18, 2019 · Atara Biotherapeutics, Inc. ATRA Shares of this California based biotech, which makes treatments for patients with cancer, autoimmune, and viral diseases, has declined 55.8% this year so far.
Management Team - Atara Biotherapeutics Utpal Koppikar joined Atara Biotherapeutics as Chief Financial Officer in June 2018. Prior to joining Atara, Utpal held several senior financial leadership positions at Gilead Sciences, including as Vice President of Corporate and Operations Finance, responsible for R&D, corporate, G&A, process development and manufacturing, and strategic sourcing. Atara Biotherapeutics, Inc. (ATRA) Stock: Is This ... Oct 18, 2019 · Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotechnology space, this is a very important ratio to consider. In terms of ATRA, the cash to share value ratio comes to 3.56. How Analysts Feel About Atara Biotherapeutics, Inc. Why Atara Biotherapeutics Stock Is Bolting Higher Today ... Why Atara Biotherapeutics Stock Is Bolting Higher Today Atara took a major step forward today in its bid to be the first to market with an off-the-shelf T-cell therapy. About - Atara Biotherapeutics
ATRA Real Time Stock Quote - Get Atara Biotherapeutics, Inc. Common Stock (ATRA) last sale data in real-time at NASDAQ.com.
According to GuruFocus Real-Time Picks, a Premium feature, Klarman divested of 842,212 shares of the Boston-based biotech company on Nov. 30. Seth
Atara's top competitors are Agenus, Puma Biotechnology and Inovio. See Atara's Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit.
Biotech Stock No. 2: Atara Biotherapeutics. Maverick Capital first bought shares of Atara Biotherapeutics Inc. (Nasdaq: ATRA) in the first quarter of 2019. Since then, it has increased its stake sixfold to more than 5 million shares. Maverick is Atara’s second-largest shareholder. And it’s in great company. The Baupost Group is the largest. 5 Beaten-Down Biotech Stocks Set to Rebound in 2020 | Nasdaq Dec 18, 2019 · Atara Biotherapeutics, Inc. ATRA Shares of this California based biotech, which makes treatments for patients with cancer, autoimmune, and viral diseases, has declined 55.8% this year so far. Atara Biotherapeutics Releases Published Clinical Results ...
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.
Atara's technology platform leverages. 02 April 2020 Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic. Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update Press Releases :: Atara Biotherapeutics (ATRA)
What's been weighing on the biotech's shares this year? Atara's shares have slumped in response to the news that its experimental, Why Atara Biotherapeutics Stock Is Imploding Today Atara Biotherapeutics, Inc. Common Stock Real Time Stock ...